Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies

키워드

참고문헌 (97)

1. Fishman JA, "Infection in organ-transplant recipients", N Engl J Med, 338, pp.1741~1751 (1998)
2. Rubin RH, "Cytomegalovirus in solid organ transplantation", Transpl Infect Dis, 3(Suppl 2), pp.1~5 (2001)
3. Freeman RB Jr., "The 'indirect' effects of cytomegalovirus infection", Am J Transplant, 9, pp.2453~2458 (2009)
4. Torre-Cisneros J, "Management of cytomegalovirus infection in solid organ transplant recipients: SET", GESITRA- SEIMC, Transplant Rev (Orlando), pp.2016, 30[DOI]
5. Reischig T, "Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies", Expert Rev Anti Infect Ther, 8, pp.903~910 (2010)
6. Roman A, "The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients", Transplant Rev (Orlando), 28, pp.84~91 (2014)
7. Fisher RA, "Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation", Transpl Infect Dis, 11, pp.195~202 (2009)
8. Sagedal S, "Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk", Clin Transplant, 21, pp.309~313 (2007)
9. Evans PC, "An association between cytomegalovirus infection and chronic rejection after liver transplantation", Transplantation, 69, pp.30~35 (2000)
10. Kotton CN, "Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation", Transplantation, 96, pp.333~360 (2013)
11. Razonable RR, "Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients", Infect Dis Clin North Am, 27, pp.317~342 (2013)
12. Sagedal S, "The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients", Am J Transplant, 2, pp.850~856 (2002)
13. Potena L, "Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection", Transplantation, 82, pp.398~405 (2006)
14. Arthurs SK, "Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation", Clin Infect Dis, 46, pp.840~846 (2008)
15. Borchers AT, "Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms", Transpl Immunol, 7, pp.75~82 (1999)
16. Paya CV, "Indirect effects of CMV in the solid organ transplant patient", Transpl Infect Dis, 1(Suppl 1), pp.8~12 (1999)
17. Reischig T, "Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis", Transplantation, 87, pp.436~444 (2009)
18. Petrakopoulou P, "Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function", Circulation, 110(11 Suppl 1), pp.II207~II212 (2004)
19. Johanssson I, "Cytomegalovirus and long-term outcome after lung transplantation in Gothenburg, Sweden", Scand J Infect Dis, 42, pp.129~136 (2010)
20. Linares L, "Influence of cytomegalovirus disease in outcome of solid organ transplant patients", Transplant Proc, 43, pp.2145~2148 (2011)
21. Gunsar F, "Late hepatic artery thrombosis after orthotopic liver transplantation", Liver Transpl, 9, pp.605~611 (2003)
22. Morris MI, "Infections transmitted by transplantation", Infect Dis Clin North Am, 24, pp.497~514 (2010)
23. Razonable RR, "Cytomegalovirus infection after liver transplantation: current concepts and challenges", World J Gastroenterol, 14, pp.4849~4860 (2008)
24. Abecassis MM, "The role of PCR in the diagnosis and management of CMV in solid organ recipients: what is the predictive value for the development of disease and should PCR be used to guide antiviral therapy?", Transplantation, 63, pp.275~279 (1997)
25. Schneider M, "Clinical significance of the single nucleotide polymorphism TLR2 R753Q in heart transplant recipients at risk for cytomegalovirus disease", J Clin Virol, 84, pp.64~69 (2016)
26. Manuel O, "Swiss Transplant Cohort Study. Influence of IFNL3", 4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation, 2015, pp.211, 906~914
27. Kang SH, "Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation", J Infect Dis, 205, pp.639~646 (2012)
28. Fishman JA, "Cytomegalovirus in transplantation - challenging the status quo", Clin Transplant, 21, pp.149~158 (2007)
29. Lumbreras C, "Cytomegalovirus infection in solid organ transplant recipients", Clin Microbiol Infect, 20(Suppl 7), pp.19~26 (2014)
30. Fryer JF, "A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology", Biologicals, 44, pp.242~251 (2016)
31. "Collaborative study to evaluate the proposed 1st WHO international standard for human cytomegalovirus (HCMV) for nucleic acid amplification (NAT)- based assays"[URL]
32. Egli A, "State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician", Clin Infect Dis, 55, pp.1678~1689 (2012)
33. Melendez D, "Immune-based monitoring for cytomegalovirus infection in solid organ transplantation: is it ready for clinical primetime?", Expert Rev Clin Immunol, 10, pp.1213~1227 (2014)
34. Fernández-Ruiz M, "Clinical immune- monitoring strategies for predicting infection risk in solid organ transplantation", Clin Transl Immunology, 3, pp.e12~ (2014)
35. Crough T, "Immunobiology of human cytomegalovirus: from bench to bedside", Clin Microbiol Rev, 22, pp.76~98 (2009)
36. Lidehall AK, "T cell control of primary and latent cytomegalovirus infections in healthy subjects", J Clin Immunol, 25, pp.473~481 (2005)
37. Sylwester AW, "Broadly targeted human cytomegalovirus- specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects", J Exp Med, 202, pp.673~685 (2005)
38. Gratama JW, "Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection", Blood, 98, pp.1358~1364 (2001)
39. Elkington R, "Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers", J Virol, 77, pp.5226~5240 (2003)
40. Manley TJ, "Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection", Blood, 104, pp.1075~1082 (2004)
41. Natori Y, "Recurrence of CMV infection and the effect of prolonged antivirals in organ transplant recipients", Transplantation, 101, pp.1449~1454 (2017)
42. Martín-Gandul C, "Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy", Transpl Int, 27, pp.1060~1068 (2014)
43. Manuel O, "Clinical experience with immune monitoring for cytomegalovirus in solid-organ transplant recipients", Curr Infect Dis Rep (2013)
44. Kumar D, "Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients", Am J Transplant, 9, pp.1214~1222 (2009)
45. Giulieri S, "QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity", Expert Rev Mol Diagn, 11, pp.17~25 (2011)
46. Connell TG, "QuantiFERON- TB gold: state of the art for the diagnosis of tuberculosis infection?", Expert Rev Mol Diagn, 6, pp.663~677 (2006)
47. Walker S, "Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV", Transpl Infect Dis, 9, pp.165~170 (2007)
48. Manuel O, "Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study", Clin Infect Dis, 56, pp.817~824 (2013)
49. Lisboa LF, "Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia", Transplantation, 93, pp.195~200 (2012)
50. Cantisán S, "Pretransplant interferon-gamma secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation", Am J Transplant, 13, pp.738~745 (2013)
51. Li CR, "Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis", Blood, 83, pp.1971~1979 (1994)
52. Lautenschlager I, "Prospective study on CMV-reactivations under preemptive strategy in CMV-seropositive adult liver transplant recipients", J Clin Virol, 57, pp.50~53 (2013)
53. Kumar D, "An interventional study using cell mediated immunity to personalize therapy for cytomegalovirus infection after transplantation", Am J Transplant, 17, pp.2468~2473 (2017)
54. Patel M, "Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients", Pediatr Transplant, 16, pp.18~28 (2012)
55. Abate D, "Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients", J Infect Dis, 202, pp.585~594 (2010)
56. Chiereghin A, "Monitoring cytomegalovirus T-cell immunity in small bowel", multivisceral transplant recipients, 2010, pp.42, 69~73
57. Costa C, "Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients", Transplant Proc, 43, pp.1159~1161 (2011)
58. Abate D, "Human cytomegalovirus- specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection", J Clin Microbiol, 50, pp.1974~1980 (2012)
59. Bestard O, "Pretransplant immediately early- 1-specific T cell responses provide protection for CMV infection after kidney transplantation", Am J Transplant, 13, pp.1793~1805 (2013)
60. Banas B, "Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients", BMC Immunol, 18, pp.15~ (2017)
61. Barabas S, "An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity", BMC Immunol, 18, pp.14~ (2017)
62. Barabas S, "Urea-mediated cross-presentation of soluble Epstein-Barr virus BZLF1 protein", PLoS Pathog, 4, pp.e1000198~ (2008)
63. Villadangos JA, "Intrinsic and cooperative antigen- presenting functions of dendritic-cell subsets in vivo", Nat Rev Immunol, 7, pp.543~555 (2007)
64. Bendall SC, "A deep profiler's guide to cytometry", Trends Immunol, 33, pp.323~332 (2012)
65. Dolton G, "More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers", Immunology, 146, pp.11~22 (2015)
66. Schmidt J, "Analysis, isolation, and activation of antigen-specific CD4(+) and CD8(+) T cells by soluble MHC-peptide complexes", Front Immunol, 4, pp.218~ (2013)
67. Gabanti E, "Predictive value of human cytomegalovirus (HCMV) T-cell response in the control of HCMV infection by seropositive solid-organ transplant recipients according to different assays and stimuli", New Microbiol, 39, pp.247~258 (2016)
68. Snyder LD, "Polyfunctional T-Cell signatures to predict protection from cytomegalovirus after lung transplantation", Am J Respir Crit Care Med, 193, pp.78~85 (2016)
69. Snyder LD, "Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis", Am J Transplant, 11, pp.553~560 (2011)
70. Gerna G, "Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation", Am J Transplant, 11, pp.2463~2471 (2011)
71. Bunde T, "Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells", J Exp Med, 201, pp.1031~1036 (2005)
72. Radha R, "Cellular immune responses to cytomegalovirus in renal transplant recipients", Am J Transplant, 5, pp.110~117 (2005)
73. Gerna G, "Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation", Am J Transplant, 6, pp.2356~2364 (2006)
74. La Rosa C, "Longitudinal assessment of cytomegalovirus (CMV)- specific immune responses in liver transplant recipients at high risk for late CMV disease", J Infect Dis, 195, pp.633~644 (2007)
75. Egli A, "Cytomegalovirus- specific T-cell responses and viral replication in kidney transplant recipients", J Transl Med, 6, pp.29~ (2008)
76. Eid AJ, "A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection", Transpl Int, 23, pp.506~513 (2010)
77. Pipeling MR, "Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients", J Infect Dis, 204, pp.1663~1671 (2011)
78. Higdon LE, "Cytomegalovirus-responsive CD8+ T cells expand after solid organ transplantation in the absence of CMV disease", Am J Transplant, 17, pp.2045~2054 (2017)
79. Lee S, "Cytomegalovirus infection alters phenotypes of different gammadelta T-cell subsets in renal transplant recipients with long-term stable graft function", J Med Virol, 89, pp.1442~1452 (2017)
80. Mena-Romo JD, "CMV-specific T-cell immunity in solid organ transplant recipients at low risk of CMV infection. Chronology and applicability in preemptive therapy", J Infect (2017)
81. Sester M, "Levels of virus- specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation", Transplantation, 71, pp.1287~1294 (2001)
82. Tu W, "T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease", Circulation, 114, pp.1608~1615 (2006)
83. Sester U, "Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation", Am J Transplant, 5, pp.1483~1489 (2005)
84. Sund F, "CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study", Clin Transplant, 24, pp.401~409 (2010)
85. Klenerman P, "Tracking T cells with tetramers: new tales from new tools", Nat Rev Immunol, 2, pp.263~272 (2002)
86. Mees ST, "Detection of different virus-specific CD8+ T cells after kidney transplantation", Surg Infect (Larchmt), 15, pp.274~282 (2014)
87. Brooimans RA, "Analytical performance of a standardized single-platform MHC tetramer assay for the identification and enumeration of CMV-specific CD8+ T lymphocytes", Cytometry A, 73, pp.992~1000 (2008)
88. Tario JD Jr, "Dextramer reagents are effective tools for quantifying CMV antigen-specific T cells from peripheral blood samples", Cytometry B Clin Cytom, 88, pp.6~20 (2015)
89. Newell EW, "Mass cytometry: blessed with the curse of dimensionality", Nat Immunol, 17, pp.890~895 (2016)
90. Krams SM, "Applying mass cytometry to the analysis of lymphoid populations in transplantation", Am J Transplant, 17, pp.1992~1999 (2017)
91. Singhal N, "MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis", Front Microbiol, 6, pp.791~ (2015)
92. Bendall SC, "Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum", Science, 332, pp.687~696 (2011)
93. Mair F, "The end of gating? An introduction to automated analysis of high dimensional cytometry data", Eur J Immunol, 46, pp.34~43 (2016)
94. Horowitz A, "Regulation of adaptive NK cells and CD8 T cells by HLA-C correlates with allogeneic hematopoietic cell transplantation and with cytomegalovirus reactivation", J Immunol, 195, pp.4524~4536 (2015)
95. Lau AH, "Mass cytometry reveals a distinct immunoprofile of operational tolerance in pediatric liver transplantation", Pediatr Transplant, 20, pp.1072~1080 (2016)
96. Ornatsky O, "Multiple cellular antigen detection by ICP-MS", J Immunol Methods, 308, pp.68~76 (2006)
97. Calarota SA, "Normalizing ELISPOT responses to T-cell counts: a novel approach for quantification of HCMV-specific CD4(+) and CD8(+) T-cell responses in kidney transplant recipients", J Clin Virol, 61, pp.65~73 (2014)

관련 논문AI추천